Skip to main content

Table 2 GRADE profile of ITF supplementation for FBG, HbA1c, and FINS levels and HOMA-IR scores in the total population and in the prediabetes and T2DM population

From: Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose–response meta-analysis of 33 randomized controlled trials

Quality assessmentSummary of findingsQuality of evidence
OutcomesRisk of biasInconsistencyIndirectnessImprecisionPublication BiasNumber of intervention/controlAbsolute effect (95% CI)Relative effecta intervention/control
FBG (Total population)No serious limitationsSerious limitationsbNo serious limitationsNo serious limitationsNo serious limitations656/651− 0.21 (− 0.33, − 0.09) mmol/l− 4.32%/0.36% moderate
HbA1C (Total population)No serious limitationsSerious limitationscNo serious limitationsNo serious limitationsNo serious limitations220/219− 0.39 (− 0.65, − 0.13) %− 4.93%/1.20% moderate
FINS (Total population)No serious limitationsVery serious limitationsdNo serious limitationsNo serious limitationsStrongly suspectede515/514− 1.22 (− 1.90, − 0.54) μU/ml− 12.62%/0.44% very low
HOMA-IR (Total population)No serious limitationsVery serious imitationsfNo serious limitationsNo serious limitationsNo serious limitations357/360− 0.57 (− 0.84, − 0.31)− 19.10%/− 1.27% low
FBG (T2DM and prediabetes)No serious limitationsNo serious limitationsNo serious limitationsNo serious limitationsNo serious limitations283/280− 0.60 (− 0.71, − 0.48) mmol/l− 7.41%/− 0.26%  high
HbA1C (T2DM and prediabetes)No serious limitationsNo serious limitationsNo serious limitationsNo serious limitationsNo serious limitations190/189− 0.58 (− 0.83, − 0.32) %− 5.15%/1.55%  high
FINS (T2DM and prediabetes)No serious limitationsVery serious limitationsgNo serious limitationsNo serious limitationsNo serious limitations232/229− 1.75 (-2.87, − 0.63) μU/ml− 20.08%/− 3.50% low
HOMA-IR (T2DM and prediabetes)No serious limitationsVery serious limitationshNo serious limitationsNo serious limitationsNo serious limitations195/197− 0.69 (− 1.10, − 0.28)− 27.63%/− 2.29% low
  1. FBG fasting blood glucose, FINS fasting insulin, HbA1c glycosylated hemoglobin, HOMA-IR homeostasis model assessment- insulin resistance, T2DM type 2 diabetes mellitus
  2. aThe relative effect is computed by calculating the weighted mean of the baseline and hypoglycemic effects
  3. bThe test for heterogeneity is significant, and the I2 is moderate, 59%
  4. cThe test for heterogeneity is significant, and the I2 is moderate, 51%
  5. dThe test for heterogeneity is significant, and the I2 represent substantial heterogeneity, 69%
  6. eThe Egger’s test for publication bias is significant (P = 0.0035)
  7. fThe test for heterogeneity is significant, and the I2 represent substantial heterogeneity, 64%
  8. gThe test for heterogeneity is significant, and the I2 represent substantial heterogeneity, 78%
  9. hThe test for heterogeneity is significant, and the I2 represent substantial heterogeneity, 81%